Embarking on gender-affirming care while undergoing treatment for cancer presents unique challenges and considerations. This situation requires a delicate balance between respecting personal gender identity goals and addressing the medical ...
Breast cancer The lifetime risk of breast cancer for cis women is approximately 12%, while the lifetime risk for cis men is approximately 0.1% (Sonnenblick et al., 2018). Research has shown that the lifetime risk of breast cancer for trans women on ...
Estrogen cypionate injections, like other forms of estrogen, are used in hormone replacement therapy for transgender women (assigned male at birth) as part of gender-affirming care to feminise secondary sexual characteristics. Here are potential ...
Estrogen cypionate injections, like other forms of estrogen, are used in hormone replacement therapy for transgender women (assigned male at birth) as part of gender-affirming care to feminise secondary sexual characteristics. Here are potential ...
Individuals with prostate cancer are typically advised against testosterone therapy as part of gender affirming care due to potential risks associated with hormone-sensitive tumors. Testosterone, a primary component of masculinizing hormone therapy, ...